Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 10 Week, Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg qd) to Twice Daily Dosing of Aliskiren (150 mg Bid) in Patients With Essential Hypertension.

NCT00654875 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00654875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00654875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 10 Week, Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg qd) to Twice Daily Dosing of Aliskiren (150 mg Bid) in Patients With Essential Hypertension.
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2008
Completion date
November 30, 2008
Enrollment
328 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension